Skip to content

The effect of lavender on pain intensity and sleep quality in patients with sickle cell disease

The effect of aromatherapy with lavender essential oil on pain intensity and sleep quality in patients with sickle cell disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20260120068622N1
Enrollment
56
Registered
2026-02-27
Start date
2026-03-09
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sickle cell disease. Sickle-cell disorders

Interventions

Intervention 1: Intervention group: Participants in the intervention group will be instructed to, for two weeks, place three drops of 100% pure lavender essential oil, prepared by Barij Essence Kashan

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Definitive diagnosis of sickle cell disease based on valid medical documentation and standard laboratory tests (such as hemoglobin electrophoresis) Age between 18 and 65 years Willingness to participate in the study and to provide informed consent Ability to read and write in Persian (for completing the questionnaires) Intact olfactory function based on self-report and a simple olfactory test A score of 5 or higher on the Pittsburgh Sleep Quality Index (PSQI) A score of 3 or higher on the Numeric Rating Scale (NRS) for pain intensity

Exclusion criteria

Exclusion criteria: Presence of severe psychiatric disorders (based on medical records). Pregnancy. Use of complementary medicine approaches (such as yoga and massage). Presence of stimulant substance use disorders (e.g., amphetamines), cannabinoid use disorders, hallucinogen use, or alcohol use or high-risk alcohol consumption within the past 12 months (based on medical records or self-report). Presence of opioid use disorder (according to clinical criteria or evidence of misuse as determined by the treating physician). Presence of acute illnesses or unstable medical conditions that would preclude safe participation in the study (based on medical records or self-report). Presence of confirmed chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease.

Design outcomes

Primary

MeasureTime frame
Pain intensity score measured by the Brief Pain Inventory. Timepoint: Measurement of pain intensity at the beginning of the study (before the intervention) and 14 days after the start of lavender essential oil administration (after the end of the intervention). Method of measurement: Brief Pain Inventory.;Pain intensity score on the Numeric Rating Scale. Timepoint: Measurement of pain intensity at the beginning of the study (before the intervention) and on days 7 and 14 after the start of lavender essential oil administration. Method of measurement: Numeric Rating Scale for pain intensity.;Sleep quality score on the Pittsburgh Sleep Quality Index. Timepoint: Measurement of sleep quality at the beginning of the study (before the intervention) and 14 days after the start of lavender essential oil administration (after the end of the intervention). Method of measurement: Pittsburgh Sleep Quality Index.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Abdollahi

Ahvaz University of Medical Sciences

abdollahi.za@ajums.ac.ir+98 61 3373 8538

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026